{"contentid": 487930, "importid": NaN, "name": "Argobio launches with 50 million euros, aiming to create pioneering biotech spinouts", "introduction": "Argobio, a newly-created start-up studio dedicated to life sciences, today announced its launch with 50 million euros ($60.3 million) of committed capital.", "content": "<p>Argobio, a newly-created start-up studio dedicated to life sciences, today announced its launch with 50 million euros ($60.3 million) of committed capital.</p>\n<p>Argobio was initiated by Kurma Partners, a Paris and Munich-based healthcare venture capital firm, and Bpifrance, the French national investment bank.</p>\n<p>Complementary strategic investors were Italy&rsquo;s privately-owned drugmaker Angelini Pharma, which gains a 30% with a loan of 15 million euros, Evotec (EVT: Xetra), a Germany-based drug discovery alliance and development partnership company, and France&rsquo;s Institut Pasteur, internationally renowned center for biomedical research.</p>\n<h2><strong>Aims for at least five ambitious biotech companies within five years</strong></h2>\n<p>The objectives of Argobio will be to create and launch, within the next five years, at least five ambitious biotech companies, in selected therapeutic areas that include rare diseases, neurological disorders, oncology and immunology. Furthermore, it will try to develop promising technological platforms for the realization of therapeutic products. All investors will have the opportunity to take stakes in the biotech companies created by Argobio.</p>\n<p>Argobio will identify, select, and incubate these projects up to company creation, providing broad expertise in the discovery and development of innovative therapeutic products from its team of highly experienced biotech entrepreneurs.</p>\n<p>Angellini chief executive Pierluigi Antonello commented: &ldquo;We are thrilled to be able to invest and be actively involved in Argobio&rsquo;s activities. Thanks to this initiative, we will be able to evaluate the most promising programs of the best European academic institutions and continue to invest in pioneering companies, which are developing terapie innovation. After the acquisition of Arvelle Therapeutics, this is a further and important step towards our ambition to become European leaders in innovation in the therapeutic areas of mental health, central nervous system and rare diseases.&rdquo;</p>\n<p>&ldquo;Building on our BRIDGE strategy and partnerships, we continue to be dedicated to making Evotec's all-modality technology platforms available to validate and accelerate therapeutic concepts from top-tier academic institutions globally. As an investor into Argobio, we are delighted to work with a group of distinguished partners and entrepreneurs to build companies committed to the maturation of first-in-class therapeutics towards drugs that which will change patients' lives and cure diseases with some of the highest medical needs,&rdquo; said Dr Werner Lanthaler, CEO of Evotec.</p>", "date": "2021-03-03 12:38:00", "meta_title": "Argobio launches with 50 million euros, aiming to create pioneering bi", "meta_keywords": "Argobio, Start-up, Angelini, Evotec, Institute Pasteur, Investment, New companies", "meta_description": "Argobio launches with 50 million euros, aiming to create pioneering biotech spinouts", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-03 12:36:52", "updated": "2021-03-03 12:45:19", "access": NaN, "url": "https://www.thepharmaletter.com/article/argobio-launches-with-50-million-euros-aiming-to-create-pioneering-biotech-spinouts", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "lab_vials_biotech_2021_big.jpg", "image2id": "lab_vials_biotech_2021_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immunologicals, Neurological, Oncology, Rare diseases", "topic_tag": "Business Financing, Companies, mergers and acquisitions", "geography_tag": "France, Germany, Italy", "company_tag": "Angelini, Argobio, BPIFRANCE FINANCEMENT SA, Evotec, Institut Pasteur, Kurma Partners", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-03 12:38:00"}